Trial Profile
A Study of a Hypertensive Population Under Treatment With Micardis and Micardis Plus Under Real Clinical Conditions With the Goal to Control the Early Morning BP Rise (SURGE II)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2014
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms SURGE II
- Sponsors Boehringer Ingelheim
- 24 Sep 2014 New trial record